# Spero Therapeutics, Inc.: Form 8-K, filed Oct 29, 2024

- Company: [Spero Therapeutics, Inc.](/companies/spro.md) (CIK 1701108)
- Form: 8-K
- Filed: 2024-10-29
- Accepted by EDGAR: Oct 29, 2024, 17:01 ET
- Period: 2024-10-29
- Accession: 0001193125-24-246627
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1701108/000119312524246627/d889032d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1701108/000119312524246627/

## Items reported

- Item 2.02: Results of operations
- Item 2.05: Exit or disposal costs
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1701108/000119312524246627/d889032d8k.htm

Filed Oct 29, 2024.
Source: SEC EDGAR, the filing index for accession 0001193125-24-246627. Last ingested by Listed: Nov 13, 2026, 16:27 ET. No prices; not investment advice.
